Assess 28-Day Survival of Top Down Approach of Slow Low-Dose Continuous Albumin + Furosemide ± Terlipressin (SAFI ± T) and N-Acetycystine Infusion and Probiotics in ACLF Patients with MELD ≥ 35, Ascites and High CVP (Central Venous Pressure) ± Organ Failure